Jeanmarie Guenot, Ph.D.
Jeanmarie Guenot, Ph.D. is a business executive with over 20 years
of experience in the pharmaceutical and biotechnology industry. She
has worked with all stages of companies, both public and private, in
pharmaceutical R&D, corporate & commercial development, business
development, project & alliance management and venture capital.
She has significant expertise and interest in building or rebuilding
companies and has worked in most major therapeutic areas, most
recently in ophthalmology as the key business and operating officer
of SKS Ocular.
Dr. Guenot founded, built and ran SKS Ocular, a start-up ophthalmic
company incubator, and SKS Ocular 1, its first portfolio of five
companies focused on dry AMD and sustained release ocular drug
delivery technologies and therapeutics for glaucoma, macular
degeneration and ocular inflammation.
From 2008 to 2009, Dr. Guenot was a business advisor for Hoffmann-La Roche in Basel and Shanghai.
Prior to that, as Vice President of Corporate & Business Development at PDL BioPharma, she led licensing,
mergers and acquisitions and alliance management for PDL’s R&D and commercial product portfolios. She
led and negotiated the Biogen Idec-PDL 50:50 co-development and co-commercialization collaboration,
which involved three Phase 2 cancer and autoimmune disease drug candidates. This $800 M transaction
included a $100 M equity investment in PDL and a therapeutic candidate with indications split between
Biogen Idec/PDL and Hoffmann-La Roche. She received BioBusiness Network’s Innovative Bio-Partnering
Award in 2005, and Deal of Distinction from the Licensing Executives Society in 2006. In 2008, she spun
product rights from the PDL-Biogen Idec collaboration to Ophthotech, a private, venture-backed
ophthalmology company. She was also a key participant in the sale of PDL's commercial and manufacturing
businesses. Dr. Guenot was a member of PDL’s Executive Team and Portfolio Management Committee. She
led the Biogen Idec-PDL Alliance and was a member of the Joint Steering Committee. She has portfolio,
project and alliance management experience in the areas of oncology, cardiovascular diseases, autoimmune
diseases, neurology and ophthalmic diseases.
Dr. Guenot started her business career at Atlas Venture, where she managed venture capital investments and
built life science companies, operating at the Board of Directors level. She started her scientific career as a
principal scientist in preclinical R&D at Hoffmann-La Roche, discovering and developing drugs for metabolic
diseases, inflammation, autoimmune diseases and oncology. Dr. Guenot trained in physical and medicinal
chemistry, with a focus in quantum mechanical and semi-empirical methods for molecular dynamics, protein
structure prediction, X-ray and NMR refinement and drug design. She earned her Ph.D. from the University of
California, San Francisco and her MBA from The Wharton School at the University of Pennsylvania.